Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 07, 2026
Why Is Progyny (PGNY) Stock Down -8.61% Today?

Why Is Progyny (PGNY) Stock Down -8.61% Today?

Key Takeaways

  • Progyny shares tumbled 8.61% to $27.61 in Friday trading, following a sharp after-hours selloff triggered by the company's second-quarter earnings report released Thursday evening.
  • Despite beating Q2 top- and bottom-line estimates, the company's Q3 revenue guidance of $335 million to $345 million came in well below Wall Street's consensus of approximately $350.6 million, rattling investor sentiment.
  • Management attributed the softer forward outlook to a more pronounced summer slowdown in member engagement, characterizing the seasonal weakness as temporary but enough to spook markets.
  • Full-year revenue guidance was modestly trimmed to $1.36 billion–$1.385 billion at the midpoint, while adjusted EPS guidance was raised to $2.04–$2.10.
  • Broader healthcare and mid-cap growth sectors showed mixed performance Friday, but PGNY's move was overwhelmingly earnings-driven rather than a sector-wide phenomenon.
  • Traders are now watching for stabilization around key technical levels and the company's next selling-season update for signs of reaccelerating growth.

Opening Summary

Shares of PGNY, the fertility and family-building benefits management company Progyny, Inc., plunged 8.61% to $27.61 during Friday's trading session, extending losses that began in after-hours trading Thursday evening. The stock closed the prior session at $30.21 and had already shed roughly 3.7% during Thursday's regular trading. The selloff was triggered by the company's second-quarter fiscal 2026 earnings results, released after the bell on August 6, where stronger-than-expected Q2 figures were overshadowed by third-quarter revenue guidance that fell materially short of analyst expectations.

Q2 Earnings: A Beat That Wasn't Enough

At first glance, Progyny's second-quarter numbers appeared solid. Revenue rose 5.3% year-over-year to $350.5 million, narrowly exceeding consensus estimates of roughly $348.5 million. Adjusted earnings per share came in at $0.55, comfortably above the analyst consensus of around $0.34 to $0.52 depending on the estimate set. Adjusted EBITDA reached $62.1 million, yielding a 17.7% margin, and gross margin expanded 180 basis points year-over-year to 25.5%, driven by efficiencies in care management and service delivery.

CEO Pete Anevski noted that member engagement trended toward the higher end of expectations during the quarter, with members continuing to pursue family-building and health and well-being services. The company also highlighted strong selling-season momentum, with early client commitments pacing meaningfully ahead of the prior year. On the capital-allocation front, Progyny repurchased nearly 1.2 million shares for $31.5 million during the quarter under its $200 million buyback program, reducing shares outstanding by approximately 12.5% since November.

Guidance Disappointment: Summer Slowdown Weighs on Q3 Outlook

The problem for investors was not the rearview mirror but the road ahead. Progyny issued third-quarter revenue guidance of $335 million to $345 million, a range whose midpoint of $340 million landed roughly 3% below the analyst consensus of approximately $350.6 million. Q3 adjusted EBITDA guidance of $56 million to $59 million and adjusted EPS guidance of $0.50 to $0.52 also came in at or below Street expectations.

Management explained on the earnings call that the company is experiencing a more pronounced summer seasonality effect, where member engagement softens during peak vacation months. CFO Mark Livingston characterized the adjustment as modest—roughly a 1% change at the midpoint—and emphasized that the company has visibility into September as appointment scheduling builds. However, the market seized on the near-term growth deceleration, punishing the stock despite management's insistence that the pattern is temporary rather than structural.

Full-Year Guidance Trimmed

For the full fiscal year 2026, Progyny narrowed its revenue outlook to $1.36 billion to $1.385 billion, representing growth of 5.5% to 7.5%. While the adjusted EPS guidance range was raised to $2.04–$2.10 from a prior range of $1.98–$2.09, the revenue midpoint came down modestly from prior guidance. Adjusted EBITDA was also narrowed to $233 million to $240 million. The slight downward revision, combined with the Q3 miss, fueled concerns that growth momentum may be decelerating faster than anticipated, particularly as the company laps the contribution from a large former client whose transition-of-care agreement ended in mid-2025.

Market Context and Trading Activity

Trading volume in PGNY was significantly elevated during Thursday's after-hours session and continued heavy into Friday, well above the stock's average daily volume of approximately 1.5 million shares. The decline far outpaced any broader healthcare-sector moves, confirming the move was company-specific. PGNY had rallied more than 27% over the prior three months, driven by optimism around the selling season and accelerating earnings, making the stock particularly vulnerable to any guidance disappointment. The selloff pushed shares below the 50-day moving average, a technical level that had previously provided support during the stock's spring and summer advance.

What Comes Next for PGNY

Looking ahead, Progyny's fundamental story remains anchored in several durable tailwinds: an expanding client base that reached 604 total clients by quarter-end, growing covered lives, and a new fully insured product offering called Progyny Select that could open additional market segments over time. The company's balance sheet remains strong, with $237 million in cash and marketable securities and no debt, providing ample flexibility for continued share repurchases and strategic investments.

However, risks remain. The competitive environment in fertility benefits is intensifying, and the company must demonstrate that the summer seasonal softness is indeed temporary when third-quarter results arrive. The upcoming 2027 selling season will be a critical catalyst—early commitments are reportedly pacing ahead of last year, which could rebuild confidence if those commitments convert into realized revenue growth. Analysts remain broadly constructive, with a consensus Moderate Buy rating and a median price target well above current levels, but the near-term narrative will be dictated by whether Q3 engagement rebounds as management expects.

Trending AI Robots

For traders seeking data-driven strategies amid volatile earnings-season moves like Progyny's, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots actively navigating current market conditions. Tickeron provides hundreds of algorithmic trading bots spanning thousands of tickers and strategies, but only the strongest performers—ranked by real-time metrics—are featured in the Trending AI Robots section. Bots vary by trading style, holding period, risk profile, and the symbols they trade, allowing users to explore approaches aligned with their own objectives. Visit the Trending AI Robots page to discover which strategies are leading in today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PGNY

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


PGNY's RSI Oscillator ascending out of oversold territory

The RSI Oscillator for PGNY moved out of oversold territory on August 25, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 40 similar instances when the indicator left oversold territory. In of the 40 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 69 cases where PGNY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on September 02, 2026. You may want to consider a long position or call options on PGNY as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PGNY just turned positive on August 31, 2026. Looking at past instances where PGNY's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PGNY advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

PGNY moved below its 50-day moving average on August 07, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PGNY crossed bearishly below the 50-day moving average on August 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PGNY broke above its upper Bollinger Band on September 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PGNY entered a downward trend on August 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PGNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.392) is normal, around the industry mean (3.748). P/E Ratio (28.185) is within average values for comparable stocks, (150.697). PGNY's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (0.927). PGNY's Dividend Yield (0.000) is considerably lower than the industry average of (0.019). PGNY's P/S Ratio (1.719) is very high in comparison to the industry average of (0.581).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 68.37B. The market cap for tickers in the group ranges from 1.01M to 356.47B. UNH holds the highest valuation in this group at 356.47B. The lowest valued company is IHGP at 1.01M.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was 2%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 54%. OSCR experienced the highest price growth at 6%, while ALHC experienced the biggest fall at -1%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 9%. For the same stocks of the Industry, the average monthly volume growth was -52% and the average quarterly volume growth was 28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 46
Price Growth Rating: 38
SMR Rating: 72
Profit Risk Rating: 86
Seasonality Score: 17 (-100 ... +100)
View a ticker or compare two or three
PGNY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools

Industry ManagedHealthCare

Profile
Details
Industry
N/A
Address
1359 Broadway
Phone
+1 212 888-3124
Employees
856
Web
https://www.progyny.com
Interact to see
Advertisement
DAKT shares are declining approximately -10% in Wednesday's session, trading near $23.91, compared to the prior close of approximately $26.57. The primary catalyst is the pre-market release of fiscal Q3 2026 earnings, in which diluted EPS of $0.06 fell significantly short of the consensus estimate of approximately $0.13–$0.15.
Shares of HRZN plunged approximately 23% in Wednesday's trading session — one of the steepest single-day declines in the company's recent history. Primary catalyst: Q4 2025 earnings released after the close on March 3 revealed net investment income (NII) per share of just $0.18, badly missing the consensus estimate of $0.26 and marking a steep sequential decline.
Palantir (PLTR) is outperforming a struggling market, rallying strongly over the past few sessions while approaching a critical resistance level near $143. With geopolitical tensions rising and defense analytics demand growing, the stock sits at a pivotal technical moment that could determine its next major move.
Investors holding record levels of protective puts means downside is heavily hedged, which often dampens crash risk but supports higher implied volatility (VIX) in the short run. The fact that the S&P 500 and Nasdaq are rising while hedging is surging suggests a “wall of worry” market: people are bullish enough to stay in, but nervous enough to pay up for insurance.
During the week of 9–15 February 2026, major U.S. equity indices finished lower overall, while Tickeron’s trending AI trading bots produced positive returns, particularly in defense and energy—two areas now directly affected by the newly opened war in Iran. With macro risk rising and volatility picking up, this divergence matters: it shows how sector‑focused, rules‑based AI strategies can still find upside when broad index exposure is negative.
Investors are furiously hedging against a potential credit market crash, just as geopolitical risk explodes with a new war in Iran. Put option open interest on major U.S. credit ETFs like HYG, JNK, LQD, and BKLN has surged to a record ~11.5 million contracts, doubling over the last 12 months and already exceeding the 2022 bear‑market peak of 10 million.
The current gap between single‑stock implied volatility and index volatility is back near October 2008 extremes, signaling that investors expect idiosyncratic risk (stock‑specific jumps) to dominate.
The HUBB/AVGO/ITA/QQQ robot is a multi-sector swing trader with a 5-minute entry / daily exit structure, capturing macro megatrends across defense, semiconductors, infrastructure, and growth tech. The LRCX/TER/AMAT/KLAC/AMKR/ASML robot is a concentrated intraday-to-swing trader operating exclusively in semiconductor equipment — one of the highest-volatility sectors in the market — on a 60-minute timeframe.
Tickeron's Defense PPA AI Trading Agent is an automated swing trading system focused exclusively on PPA — the Invesco Aerospace & Defense ETF. Designed with a 60-minute entry timeframe and daily timeframe exit signals, the robot balances intraday precision with longer-duration swing holding, allowing it to capture meaningful price moves in one of the most momentum-driven sectors of 2025–2026.
MRNA surged approximately +16.07% on March 4, 2026, closing at $57.84, up from the prior session's close of $49.83. The primary catalyst was Moderna's announcement of a landmark settlement in its long-running patent dispute over lipid nanoparticle (LNP) technology used in its mRNA vaccines.
Shares of The Trade Desk (TTD) surged +28.05% on March 5, 2026, reaching $32.23 from a prior close of $25.17. The primary catalyst was CEO Jeff Green's record insider purchase of approximately 6 million shares worth ~$148 million — the largest insider buy in the company's history.
AEO shares are trading at $19.89, down $2.56 or -11.40% from the prior session's close of $22.45. The primary catalyst is deeply disappointing Q1 fiscal 2026 operating income guidance of just $20–$25 million, which badly missed analyst expectations.
CIEN shares plunged 14.25% on March 5, 2026, trading at $294.59 versus the prior session's close of $343.55 — a decline of $48.96 per share. The steep sell-off came despite a strong earnings beat: adjusted EPS of $1.35 crushed the consensus estimate of $1.05 by 28.6%, and revenue of $1.43 billion rose 33% year-over-year.
Shares of Victoria's Secret & Co. (VSCO) tumbled approximately 11.87% in early trading on March 5, falling from a prior close of $60.01 to an intraday price near $52.89, with an intraday low of $51.61. The steep decline came despite a Q4 2025 earnings beat, with adjusted EPS of $2.77 topping the consensus estimate of $2.46 and revenue of $2.27 billion exceeding the expected $2.22 billion.
AMPX shares surged +18.57% in today's session, trading at $14.88 versus the prior close of $12.55. Primary catalyst: Q4 and full-year fiscal 2025 earnings, reported before the open, delivered a decisive beat on both EPS and revenue expectations.
EXPE shares are trading up approximately +9.70% intraday on March 5, 2026, rising from a prior close of $221.25 to around $242.71. March 5 is the stock's ex-dividend date for a newly raised quarterly dividend of $0.48 per share — a 20% increase from the prior payout — signaling strong management confidence in cash generation.
SES shares are down approximately 30% intraday on Thursday, March 5, 2026, trading near $1.19 against the prior session's close of $1.71. The primary catalyst is deeply disappointing 2026 revenue guidance of $30–$35 million — roughly 41% below the Wall Street consensus of $51.67 million.
What if a single trading robot could harvest volatility across semiconductors, oil, and communication technology — simultaneously — while filtering out the noise that burns most active traders? That's exactly what the Semiconductors, Oil & Energy, Communication Tech AI Trading Agent delivers. Over the past 364 days (March 5, 2025 – March 4, 2026), this agent generated a Total Net Profit of $20,641.78 on $500-per-trade sizing — an eye-catching Annualized Return of 68.58%. With 1,534 closed trades, a 61.86% win rate, and a dominant Profit Factor of 3.02
What if an AI trading agent could turn market chaos into a 45.55% annualized return? That's exactly what Tickeron's HUBB, AVGO, ITA, QQQ – AI Trading Agent (4 Tickers, 5min) has delivered across 106 days of live trading — posting $11,605.87 in total net profit from a per-trade allocation of $2,500–$8,250, a 69.59% win rate across 444 closed trades, and a Profit Factor of 2.18.
83.97% Win Rate | 87.10% Annualized Return | $44,879.15 Total Net Profit | Profit Factor: 4.92 | Sharpe Ratio: 1.13